Literature DB >> 11104034

DNA replication error is frequent in ovarian granulosa cell tumors.

M Suzuki1, M Ohwada, Y Saga, K Ochiai, I Sato.   

Abstract

DNA replication errors (RER) have been detected in epithelial ovarian cancers, as well as in other human tumor types. These observations suggest that this genetic defect is present in ovarian granulosa cell tumors, and that a DNA mismatch repair deficiency may be involved in their development and/or progression. We therefore assayed tissue samples from 29 patients with granulosa cell tumors for RER, using polymerase chain reaction (PCR) and 5 microsatellite markers. The RER were observed at greater than or equal to 1 loci in 15 (58%) of 26 informative cases. The incidence of RER was unrelated to the patient's age or the histologic subtype or clinical stage of the tumors. The RER, however, were observed in 57% (8/14) of the informative patients with stage IA disease. These findings suggest that a DNA mismatch repair deficiency may contribute to the pathogenesis of ovarian granulosa cell tumors, and that this deficiency may be an early event in their development and/or progression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11104034     DOI: 10.1016/s0165-4608(00)00269-7

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  3 in total

1.  Error-promoting DNA synthesis in ovarian cancer cells.

Authors:  Heqiao Dai; Robert J Hickey; Jianying Liu; Robert M Bigsby; Carita Lanner; Linda H Malkas
Journal:  Gynecol Oncol       Date:  2013-07-12       Impact factor: 5.482

2.  Promoter hypermethylation of MGMT, CDH1, RAR-beta and SYK tumour suppressor genes in granulosa cell tumours (GCTs) of ovarian origin.

Authors:  V S Dhillon; A R Young; S A Husain; M Aslam
Journal:  Br J Cancer       Date:  2004-02-23       Impact factor: 7.640

3.  Molecular pathogenesis in granulosa cell tumor is not only due to somatic FOXL2 mutation.

Authors:  Wen-Chung Wang; Yen-Chein Lai
Journal:  J Ovarian Res       Date:  2014-09-06       Impact factor: 4.234

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.